The Swiss biotech company AB2Bio has been working for some time on tadekinig alfa, a medicine that blocks the IL18 pathway. Today they received news that the medicine has been granted both “Breakthrough Therapy” and “Orphan” status by the FDA.read more
TrialReach: a new way to match patients with clinical trials
TrialReach is an interesting new service for matching clinical trials with patientsto develop their service for matching patients with available clinical trials. This is a really cool idea. One of the things holding back research into rare diseases like SJIA is getting enough participants into the clinical trials so that the research can happen.read more
Round up of clinical trials in Systemic JIA
We did a check on the awesome clinicaltrials.gov website recently to see what clinical trials were happening for SJIA. The good news is that there are 7 total: 4 that are currently recruiting for patients, and another 3 that are in the planning stages but haven’t started recruiting yet.read more